News & Updates
Filter by Specialty:

Two-drug combo rises to the challenge as 1L Tx for mTNBC
02 Jul 2025
byAudrey Abella
In the primary analysis of the ASCENT-04/KEYNOTE-D19 study, a combination regimen comprising sacituzumab govitecan (SG) and pembrolizumab delivers significant progression-free survival (PFS) benefit in women with previously untreated PD-L1+ advanced triple-negative breast cancer (TNBC).